Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 334Magnetic Resonance Spectroscopy 334Radiotherapy 315Cyclophosphamide 295pembrolizumab 281Cisplatin 267Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 204Bevacizumab 186Gemcitabine 178venetoclax 172Radiosurgery 169Capecitabine 164Oxaliplatin 163fludarabine 161Nivolumab 156Paclitaxel 155Standard of Care 136Surveys and Questionnaires 130Surgical Procedures, Operative 130Dexamethasone 126Fluorouracil 124Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104Azacitidine 101atezolizumab 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × Trabedersen × Clear all
NCT06579196 2025-07-24

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

University of Nebraska

Phase 1/2 Recruiting
45 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡